Top picks 2012: Cubist Pharmaceuticals
A solid pipeline and possible buyout interest should buoy stock.
The drug company's early focus was on the development of "next-generation" antibiotics to treat "super bugs" that have become resistant to traditional therapies. Its lead product in this category, Cubicin, has on the market for several years now.
As the company's revenues have grown, management has taken the opportunity to expand into other "niche" areas as well. The company's mission is now to develop and commercialize products that address a variety of unmet needs in the acute care environment (primarily in the area of antibiotics).
In addition to a fairly advanced pipeline of new antibiotics, the company also has a number of agreements in place with other pharmaceutical companies. This allows it to both co-promote certain antibiotics sold by those companies, as well as to develop new compounds based on the technology libraries of other companies and research institutes.
Cubist has a solid pipeline and strong revenue stream on the fundamental side, and its stock has shown some of the best relative strength versus other stocks in the biotech sector and the market as a whole over virtually any time period you choose to look.
And while the stock has tried our patience at times over the past 12 years, its current relative strength suggests a very strong reason to be bullish. Indeed, it appears to once again be gearing up for a long run that could result in another doubling or tripling of our money before it settles into a new trading range at higher levels.
While Cubist's current market cap makes it difficult to tell what sort of premium shareholders might receive in a buyout offer. However, it's worth noting that, on more than one occasion over the past 12 to 18 months, there has been "intriguing" action in the company's call options.
It is quite possible that 2012 will be the year that a large pharmaceutical company finally makes a public offer for Cubist. Please note, however: One should never buy a stock solely in the hope of a buyout.
Meanwhile, we consider CBST a "buy" under $40 and a "very strong buy" under $36.
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Fed may start tapering in just a few months. Here are a few of the likely winners and losers.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.